Clinical Trial Update: Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of GTI-2040 and cytarabine in patients with refractory or relapsed acute myeloid leukemia. The study has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• GTI-2040 (GTI-2040)

Snippet

Sponsor: Aptose Biosciences Inc. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-07-27